To find bioequivalence study sponsors before they pick a CRO, start from the molecule, not the trial. A generic or 505(b)(2) developer runs its bioequivalence study before it files, and regulators keep the filing confidential until approval. The sponsor is invisible at the moment it is buying. What is public is the reference product's patent and exclusivity calendar, FDA's study recommendations for that product, and each developer's past behaviour. Together they tell you who will need a study and roughly when.
TL;DR: Trial registries and approval lists show bioequivalence work after the CRO is chosen. The early signals are Orange Book patent and exclusivity dates, the four-year mark on new chemical entities, new and upcoming FDA product-specific guidances, and the portfolio habits of likely filers. Build a list of molecules losing protection in 24 to 48 months, map likely filers to each, and use approvals and registries to learn who outsources and to whom.
Why are bioequivalence sponsors invisible until it is too late?
Three rules combine to hide them. The study comes before the application, the application is confidential, and the main US registry rule does not cover Phase 1 studies.
An executive at a bioequivalence and biosimilar CRO told us the practical effect: by the time a sponsor shows up in a trial database, it has already signed with a CRO.
- The study precedes the filing. An abbreviated new drug application has to contain evidence that the product is bioequivalent to the reference listed drug, with a complete study report, or grounds for waiving the in vivo study. The CRO is chosen before anything reaches FDA.
- The filing is confidential. FDA does not publicly disclose the existence of an application or abbreviated application before an approval or tentative approval letter, unless it has already been disclosed (21 CFR 314.430).
- Registration is not required for most of these studies in the US. The federal registration rule defines an applicable drug clinical trial as one whose study phase is other than Phase 1. A standard healthy-volunteer bioequivalence study sits outside it. Searching ClinicalTrials.gov for "bioequivalence" returns the studies sponsors chose to register, not the market.
A BD lead at a mid-size CRO described the general problem this way: "the challenge in our industry is getting the timing right because one clinical trial can be spaced 12 months apart".
Track buying signals across your accounts
Real-time alerts on leadership changes, earnings, hiring, and news — from 1,000+ sources.
How does generic and 505(b)(2) development create study demand?
Every ANDA has to show bioequivalence to its reference product, every 505(b)(2) application has to address bioavailability, and the timing of both is set by dates that are public years ahead.
The dates that drive the calendar:
- Five-year new chemical entity exclusivity. No ANDA or 505(b)(2) application for the same active moiety can be submitted for five years after approval, or four years if it contains a Paragraph IV certification challenging a listed patent. Developers who want to file on that four-year mark need a finished study by then.
- Three-year exclusivity. For new clinical investigations, FDA will not approve a competing application for those conditions of approval for three years. This blocks approval, not submission.
- The 30-month stay. If the patent owner sues within 45 days of receiving notice of a Paragraph IV certification, approval can be held for 30 months.
- 180-day exclusivity. First applicants with a Paragraph IV certification can earn 180 days during which later applicants are not approved. So several companies race for the same filing day.
- The review clock. Under the GDUFA III commitment letter, FDA's goal is to act on 90 percent of standard original ANDAs within 10 months of submission.
A 505(b)(2) application covers a modification of a listed drug, such as a new dosage form or indication, and needs only the information that supports the modification. It still has to address bioavailability, so these sponsors often buy comparative pharmacokinetic studies too.
Biosimilars follow a separate statute. A biosimilar application cannot be submitted until 4 years after the reference product was first licensed, and cannot be approved until 12 years after, according to FDA's Purple Book background page. In October 2025 FDA published a draft guidance on when comparative efficacy studies are needed, and said such studies take one to three years and cost about $24 million on average.
“We had a variety of tools, and that was the pain — the variety. We had to go to multiple places to get streamlined data.”
Lyndsay Thomson
Head of Sales Operations, Cytel
Which public sources reveal what, and how early?
Sources that describe the reference product are early. Sources that describe the generic applicant are late. Build the list from the first group and qualify accounts with the second.
| Source | What it shows | Timing relative to CRO selection |
|---|---|---|
| Orange Book data files | Patent expiry dates, exclusivity codes and expiry dates, applicant, reference listed drug and reference standard for every product. Updated monthly | Years ahead. The primary list-building source |
| Product-specific guidances | FDA's recommended bioequivalence approach for a specific reference product | Ahead. A new or revised guidance settles the expected design |
| Upcoming product-specific guidances | Guidances planned for the next 12 months: active ingredient, route and dosage form, reference product number, planned month | Up to 12 months ahead of the guidance itself |
| Purple Book | Licensed biologics, biosimilars and exclusivity information | Years ahead for biosimilar targets |
| Paragraph IV certification list | Per product: date of first Paragraph IV submission and number of potential first-applicant ANDAs. It does not name the applicants | After. Those filers finished their studies |
| CTRI (India) | Registers bioavailability and bioequivalence studies, and since 1 April 2018 only before first enrolment | At or just before study start. The CRO is already engaged |
| EU CTIS | For adult Phase 1 and bioequivalence trials, sponsor and site details publish at the authorisation decision. Remaining fields publish 30 months after the trial ends | At authorisation. The CRO is already engaged |
| ClinicalTrials.gov and WHO ICTRP | Voluntarily registered US studies; ICTRP is one search point across registries, not a registry itself | After, and incomplete |
| First generic approvals | ANDA number, generic name, applicant, brand name, approval date. 88 listed for 2026 as of early October | Long after. Shows which companies win first-to-market races |
| Drugs@FDA | Approvals, labels, letters and reviews, mostly for products approved since 1998. Updated daily | Long after. Shows each applicant's full approval history |
| EMA public assessment reports | How EMA assessed each centrally authorised medicine | Long after. Shows who files in Europe and on what evidence |
The late sources still matter. A registry record names the sponsor and the study sites, so a company's past records show where it runs studies and whether it outsources. Buyers described doing that qualification by hand. A lead-generation analyst at a bioequivalence CRO told us the team would "manually fetch the companies, go to website, identify product portfolio" for every prospect.
How do you build a molecule-first target list?
Pick the molecules first, then attach likely filers to each, then rank by how soon a filer has to commit to a study.
1. Pull the expiry calendar. From the Orange Book patent and exclusivity files, list reference products whose last listed patent or exclusivity expires in the next 24 to 48 months. Add every new chemical entity that reaches its four-year mark in the next 12 to 24 months. The 24 to 48 month window is a planning range, not a regulatory number. Tighten it against your own deal history.
2. Keep the molecules your clinic can run. Filter by dosage form and route, then read the product-specific guidance for each. The recommended design tells you whether the work fits your capabilities.
3. Attach likely filers. For each molecule, list companies that already hold approved ANDAs for the same dosage form or the same therapeutic neighbours (Orange Book products file, application type A). Add companies that appear repeatedly in the first generic approvals list. Firms that chase first filings tend to do it again.
4. Qualify each filer. Check pipeline and product pages, the Paragraph IV list for molecules they have probably already filed on, and registry history for where their past studies ran.
5. Rank by time to commitment. Score each molecule and filer pair by months until the first legal filing day or the expiry date. Work the pairs that are 12 to 30 months out. Closer than that, expect an incumbent.
For the same routine across all trial phases, see how to find clinical trial sponsors before the RFP and CRO and CDMO sales prospecting.
“All of the vendors that I've worked with, all of the onboarding that I have had to deal with, I will say, hands down, Salesmotion was the easiest that I have had.”
Lyndsay Thomson
Head of Sales Operations, Cytel
Who should you contact at a generic or 505(b)(2) sponsor?
Contact the people who own the filing calendar and the study budget, not the C-suite.
| Function | Typical titles | Why they matter |
|---|---|---|
| Clinical and bioequivalence | Head of clinical research, head of BA/BE, clinical pharmacology lead | Owns study design and CRO performance |
| Regulatory affairs | Head of regulatory affairs, ANDA or US regulatory lead | Owns the filing date the study must hit |
| Portfolio and IP | Head of portfolio, product selection or IP strategy | Decides which molecules enter development, 12 months or more before the study |
| Outsourcing | Head of clinical outsourcing, procurement or category manager | Runs vendor qualification and rate cards |
Buyers on recent calls named outsourcing, procurement and category management as the door-openers for new accounts, and the hardest titles to find. At a small 505(b)(2) company the list collapses to the chief scientific officer and the head of clinical operations.
Portfolio and IP contacts are the earliest useful conversation. Bioanalytical CRO business development covers the adjacent lab-side contacts, and industry versus academic sponsors explains how to clean sponsor lists.
Worked example: a fictional molecule, dated
This example is illustrative. Molecule X and its dates are invented to show the arithmetic.
Molecule X is an oral tablet, a new chemical entity approved on 14 June 2023.
- Five-year exclusivity ends 14 June 2028. With a Paragraph IV certification, the first legal ANDA submission day is 14 June 2027.
- Last listed patent expires in 2034.
- A product-specific guidance is on FDA's upcoming list, planned for early 2027.
Read from October 2026, that gives two groups of sponsors.
Group one wants to file on 14 June 2027 and share 180-day exclusivity. Its pivotal study has to finish, with a complete report, before that date. Eight months out, those sponsors have a CRO. The window to win that work was early 2026 or before.
Group two will not challenge the patents and plans to launch at expiry in 2034. Its studies sit years away. It belongs on the list with a 2031 review date.
A BD team that first noticed Molecule X when it appeared on the Paragraph IV list in mid 2027 saw a count of first applicants and no names, 12 months or more after the CRO decisions. The same team running the four-year screen in 2025 would have had Molecule X and its probable filers on a call list while protocols were unwritten.
The action is not to chase Molecule X. It is to pull every new chemical entity approved in 2024, whose first filing day falls in 2028, and start those conversations now.
Where does account monitoring fit?
Molecule screening tells you which companies to watch. Account monitoring tells you when one of them moves.
Signals worth watching on each likely filer:
- Hiring for bioequivalence, clinical pharmacology, regulatory affairs or clinical outsourcing roles
- Funding, licensing deals or a partnership covering specific molecules
- Press releases on tentative approvals and new filings, which show pace
- New registry records, which show where the current study runs
Saved searches and a spreadsheet can do this. So can a monitoring platform. Salesmotion, as one option, monitors a named account list across news, filings, hiring, funding and clinical trial activity, and supplies contacts for each account. The CRO page and the life sciences overview describe that setup. The molecule screen stays a public-source exercise either way.
For sponsors at the other end of development, the same date-driven logic applies to PDUFA dates and NDA or BLA filings.
Frequently Asked Questions
Does FDA publish which companies have filed an ANDA?
No. FDA does not disclose the existence of a pending abbreviated application before an approval or tentative approval letter, unless it was already made public. The Paragraph IV certification list shows that ANDAs with patent challenges exist for a product and how many potential first applicants there are, but it does not name them.
Are bioequivalence studies listed on ClinicalTrials.gov?
Some are, by choice. The US registration rule applies to drug trials whose phase is other than Phase 1, so a standard healthy-volunteer bioequivalence study is not covered. India's CTRI registers bioavailability and bioequivalence studies before enrolment, and the EU's CTIS publishes sponsor and site details for these trials at authorisation.
How early do generic sponsors choose a bioequivalence CRO?
Before the study, and the study comes before the filing. For a sponsor targeting the first legal filing day on a new chemical entity (four years after approval with a Paragraph IV certification), the CRO decision falls well before that day. A working range for outreach is 12 to 30 months ahead of the filing or expiry date, adjusted to your own deal history.
What is the difference between an ANDA and a 505(b)(2) sponsor for a CRO?
An ANDA sponsor copies a reference product and needs bioequivalence evidence. A 505(b)(2) sponsor modifies a listed drug, for example with a new dosage form, and submits the information that supports the change. ANDA sponsors are often portfolio companies with repeat study volume. 505(b)(2) sponsors are often small, with one programme and a senior scientific buyer.
How do you find biosimilar sponsors early?
Start from the reference biologic. A biosimilar application cannot be submitted until 4 years after the reference product was first licensed and cannot be approved until 12 years after. The Purple Book lists licensed biologics, existing biosimilars and exclusivity information, which shows which reference products are already crowded and which are open.
The sponsors who will need a study in 2028 are choosing molecules this year. The dates that tell you which ones are already published.
